Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CAR-T update

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 19, 2023 4:34pm

183 Views

Post# 35743451

RE:RE:RE:CAR-T update

UCLA is another step closer in the development of an “off-the-self“ allogeneic CAR-T therapy.

When combined with ONCYs pelareorep CAR-T durability is enhanced in the treatment of solid tumors.

https://www.regmednet.com/breaking-new-ground-on-an-allogeneic-immunotherapy/

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale